News for Healthier Living

Study Identifies Potential RAS Inhibitor-Immunotherapy Strategy for Pancreatic Cancer

This study co-led by Dana-Farber Cancer Institute suggests that long-lasting durable remissions for patients with pancreatic cancer might be possible with a novel combination of immunotherapy and RAS-targeted therapy. Immunotherapies typically focus on the activation of cytotoxic CD8 T cells, but this study suggests that tumor-specific CD4 T cells could control pancreatic cancer by coordinating innate immune cells against the disease when stimulated through IL-21 signaling alongside treatment with a KRAS inhibitor.

September 23, 2026


October 2 2026

October 1 2026

September 30 2026

September 29 2026

September 28 2026

September 27 2026

September 25 2026

September 24 2026

September 23 2026

September 22 2026

September 21 2026